Two Sigma Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Two Sigma Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-83,500	Closed	-$6.87M	–	3124
2024 Q2	$6.87M	Sell	83,500 -96,800	-54%	-$8.06M	0.02%	871
2024 Q1	$15.7M	Sell	180,300 -9,500	-5%	-$850K	0.04%	510
2023 Q4	$18.3M	Buy	+189,800	New	+$16.8M	0.04%	447
2021 Q4	–	Sell	-4,000	Closed	-$309K	–	4301
2021 Q3	$309K	Sell	4,000 -400	-9%	-$31.6K	﹤0.01%	3651
2021 Q2	$367K	Buy	+4,400	New	+$349K	﹤0.01%	3344
2020 Q3	–	Sell	-3,300	Closed	-$407K	–	3095
2020 Q2	$407K	Sell	3,300 -6,700	-67%	-$666K	﹤0.01%	2160
2020 Q1	$845K	Buy	10,000 +5,000	+100%	+$431K	0.01%	1541
2019 Q4	$423K	Sell	5,000 -7,200	-59%	-$544K	﹤0.01%	2918
2019 Q3	$822K	Sell	12,200 -4,200	-26%	-$323K	﹤0.01%	2146
2019 Q2	$1.41M	Buy	+16,400	New	+$1.4M	﹤0.01%	1681
2017 Q2	–	Sell	-2,300	Closed	-$202K	–	2961
2017 Q1	$202K	Buy	+2,300	New	+$205K	﹤0.01%	2719
2016 Q4	–	Sell	-28,200	Closed	-$2.61M	–	3104
2016 Q3	$2.61M	Buy	+28,200	New	+$2.66M	0.01%	1268
2016 Q2	–	Sell	-3,000	Closed	-$247K	–	2916
2016 Q1	$247K	Buy	+3,000	New	+$244K	﹤0.01%	2484

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments's BMRN Position: Q2 2026 in Review

Two Sigma Investments reduced its BioMarin Pharmaceuticals (BMRN) stake by 35% in Q2 2026, selling an estimated $860K and leaving 28,775 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3171.

Two Sigma Investments first reported a position in BMRN in Q2 2013 and has held it in 40 quarters since. The position peaked at $82.7M in Q1 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Two Sigma Investments held 28,775 shares of BioMarin Pharmaceuticals worth $1.65M as of Q2 2026.
Two Sigma Investments sold 15,700 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $860K.
BioMarin Pharmaceuticals made up ﹤0.01% of Two Sigma Investments's portfolio in Q2 2026, its #3171 holding.
Two Sigma Investments first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
Two Sigma Investments's BioMarin Pharmaceuticals position peaked at $82.7M in Q1 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.